- Home
- AIRT vs CELU Comparison
AIRT vs CELU Comparison
Compare AIRT & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRT
- CELU
- Stock Information
- Founded
- AIRT 1980
- CELU 2016
- Country
- AIRT United States
- CELU United States
- Employees
- AIRT N/A
- CELU N/A
- Industry
- AIRT Air Freight/Delivery Services
- CELU Biotechnology: Pharmaceutical Preparations
- Sector
- AIRT Consumer Discretionary
- CELU Health Care
- Exchange
- AIRT Nasdaq
- CELU Nasdaq
- Market Cap
- AIRT 61.2M
- CELU 56.9M
- IPO Year
- AIRT N/A
- CELU N/A
- Fundamental
- Price
- AIRT $18.35
- CELU $1.68
- Analyst Decision
- AIRT
- CELU Strong Buy
- Analyst Count
- AIRT 0
- CELU 1
- Target Price
- AIRT N/A
- CELU $6.00
- AVG Volume (30 Days)
- AIRT 1.4K
- CELU 66.6K
- Earning Date
- AIRT 11-12-2025
- CELU 11-14-2025
- Dividend Yield
- AIRT N/A
- CELU N/A
- EPS Growth
- AIRT N/A
- CELU N/A
- EPS
- AIRT N/A
- CELU N/A
- Revenue
- AIRT $279,216,000.00
- CELU $40,578,000.00
- Revenue This Year
- AIRT N/A
- CELU N/A
- Revenue Next Year
- AIRT N/A
- CELU $76.00
- P/E Ratio
- AIRT N/A
- CELU N/A
- Revenue Growth
- AIRT N/A
- CELU N/A
- 52 Week Low
- AIRT $14.56
- CELU $1.00
- 52 Week High
- AIRT $26.70
- CELU $4.35
- Technical
- Relative Strength Index (RSI)
- AIRT 26.31
- CELU 42.55
- Support Level
- AIRT $20.93
- CELU $1.62
- Resistance Level
- AIRT $21.00
- CELU $1.83
- Average True Range (ATR)
- AIRT 0.34
- CELU 0.16
- MACD
- AIRT -0.36
- CELU 0.01
- Stochastic Oscillator
- AIRT 0.00
- CELU 45.00
About AIRT Air T Inc.
Air T Inc together with its subsidiaries provides air freight service to the express delivery industry. The company's operating segments include Overnight air cargo, Ground equipment sales, Commercial jet engines, and parts, Corporate, and Others. The company generates maximum revenue from the Commercial Jet Engines and Parts segment.
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.